Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 10:45AM EDT. Market open.
| Previous close | 1.5500 |
| Open | 1.5500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.5500 - 1.5500 |
| 52-week range | 1.5150 - 2.9150 |
| Volume | |
| Avg. volume | 6,801 |
| Market cap | 7.823B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 15.50 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.06 (3.78%) |
| Ex-dividend date | 31 Jul 2023 |
| 1y target est | N/A |
- Investing.com
Cevira Phase III trial for non-surgical HSIL treatment meets primary endpoint
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).
© 2024 Yahoo. All rights reserved.